Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1062 - Phase 2 KEYNOTE-164 Study of Pembrolizumab (pembro) Monotherapy for Patients (pts) With Previously Treated, Mismatch Repair–Deficient (dMMR) Advanced Colorectal Cancer (CRC): Primary and Japan Subgroup Analyses


24 Nov 2018


Poster display - Cocktail


Targeted Therapy;  Immunotherapy

Tumour Site

Colon and Rectal Cancer


Hiroki Hara


Annals of Oncology (2018) 29 (suppl_9): ix28-ix45. 10.1093/annonc/mdy431


H. Hara1, T. Yoshino2, H. Taniguchi3, K. Akagi4, K. Shitara5, T. Masuishi3, Y. Kuboki6, T. Shimamoto7, K. Ueki7, S.R. Han7, K. Noguchi7, L.A. Diaz8

Author affiliations

  • 1 Gastroenterology, Saitama Cancer Center, 362-0806 - Ina/JP
  • 2 Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 3 Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Gastroenterology, Saitama Cancer Center, Ina/JP
  • 5 Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 6 Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 7 Oncology Science Unit, MSD K.K., Tokyo/JP
  • 8 Translational Medicine, Sidney Kimmel Cancer Center at Johns Hopkins University, Baltimore/US

Abstract 1062


A high level of microsatellite instability (MSI-H) and abnormal expression of MMR proteins is indicative of a dMMR tumor. Prior reports suggest that anti–PD-1 antibody therapy provides durable responses in pts with dMMR cancers. We report primary outcomes from cohort A and the Japan subgroup of the KEYNOTE-164 study of pts with dMMR CRC (NCT02460198).


Pts with metastatic CRC previously treated with standard therapies (fluoropyrimidine, oxaliplatin, and irinotecan), with dMMR or MSI-H confirmed locally by IHC or PCR, were enrolled. Eligible pts received pembro 200 mg Q3W for 2 years or until progression, unacceptable toxicity, or withdrawal of consent. Tumor response was assessed every 9 weeks per RECIST v1.1 by independent review. The primary end point was objective response rate (ORR); secondary end points included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Data cutoff was Feb 10, 2017.


Of 61 pts enrolled, median age was 53 y in the overall cohort and 51 y in the Japan subgroup; 59% and 43% were male, respectively. Most pts received 2 prior (46% and 29%) or ≥ 3 prior (44% and 71%) lines of therapy. Median duration of follow-up was 13.2 mo (range, 0.2-16.9) in the overall cohort and 13.2 mo (8.0-16.9) in the Japan subgroup. In the overall cohort, ORR was 28% (17 PR; 95% CI, 17-41), DCR was 51% (95% CI, 38-64), and median DOR was NR (range, 2.9+ to 12.5+ mo). The 12-mo PFS and OS rates were 34% and 72%. In the Japan subgroup (n = 7), ORR was 29% (2 PR; 95% CI, 4-71), DCR was 57% (95% CI, 18-90), and median DOR was NR (range, 10.2+ to 10.4+ mo); 12-mo PFS and OS rates were 29% and 57%. Treatment-related AEs occurred in 35/61 (57%) and 5/7 (71%) of the overall cohort and Japan subgroup. Immune-mediated AEs and infusion reactions occurred in 11/61 (18%) and 2/7 (29%), respectively. There were no treatment-related deaths.


Pembro provided durable antitumor activity in heavily pretreated pts with dMMR CRC in the overall cohort and Japan subgroup, with a safety profile consistent with that previously observed for pembro.

Editorial acknowledgement

Medical writing and/or editorial assistance was provided by Julia Burke, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Clinical trial identification

164-07, Jan 3, 2018 NCT02460198.

Legal entity responsible for the study

Merck & Co., Inc., Kenilworth, NJ, USA.


Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.


H. Hara: Honoraria: Chugai, Taiho, Merck Serono, Yakult Honsha, Lilly, Consulting, Ono, Chugai, Research, AZ, Chugai, Merck Serono, MSD, Ono, Taiho, Takeda, Boehringer Ingelheim, Dainippon Sumitomo, Daiichi Sankyo, Lilly. T. Yoshino: Research Funding Sumitomo Dainippon Pharma Co., Ltd. H. Taniguchi: Grants: Takeda; Personal fees: Chugai, Taiho. K. Shitara: Honoraria: Novartis, AbbVie, Yakult; Consulting: Astellas, Lilly, BMS, Takeda, Pfizer, Ono; Research: Dainippon Sumitomo, Lilly, MSD, Daiichi Sankyo, Taiho, Chugai, Ono. Y. Kuboki: Grants: Taiho, Daiichi-Sankyo, Takeda, AstraZeneca, Incyte; Personal fees: Taiho. T. Shimamoto, K. Ueki: Employment, stock ownership: Merck & Co., Inc. S.R. Han, K. Noguchi: Employment, stock ownership: MSD K.K. L.A. Diaz: Employment, stock ownership: Personal Genome Diagnostics; Travel: Merck; Royalties/patents/intellecutal property: Personal Genome Diagnostics, PapGene, Inostics. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.